Northern Trust’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-287,968
| Closed | -$29.4M | – | 4547 |
|
|
2023
Q2 | $29.4M | Buy |
287,968
+5,120
| +2% | +$485K | 0.01% | 1327 |
|
|
2023
Q1 | $25.7M | Buy |
282,848
+10,957
| +4% | +$643K | 0.01% | 1389 |
|
|
2022
Q4 | $10.3M | Buy |
271,891
+13,498
| +5% | +$465K | ﹤0.01% | 1985 |
|
|
2022
Q3 | $6.49M | Sell |
258,393
-2,512
| -1% | -$69.6K | ﹤0.01% | 2294 |
|
|
2022
Q2 | $7.93M | Sell |
260,905
-7,650
| -3% | -$228K | ﹤0.01% | 2201 |
|
|
2022
Q1 | $8.8M | Sell |
268,555
-7,625
| -3% | -$226K | ﹤0.01% | 2225 |
|
|
2021
Q4 | $7.28M | Sell |
276,180
-148
| -0.1% | -$11.5K | ﹤0.01% | 2461 |
|
|
2021
Q3 | $27.8M | Sell |
276,328
-12,768
| -4% | -$1.5M | ﹤0.01% | 1545 |
|
|
2021
Q2 | $40.9M | Buy |
289,096
+157,277
| +119% | +$17.8M | 0.01% | 1300 |
|
|
2021
Q1 | $13.1M | Buy |
131,819
+6,639
| +5% | +$774K | ﹤0.01% | 2112 |
|
|
2020
Q4 | $15.5M | Buy |
125,180
+4,718
| +4% | +$620K | ﹤0.01% | 1972 |
|
|
2020
Q3 | $11.7M | Sell |
120,462
-9,412
| -7% | -$1.18M | ﹤0.01% | 2011 |
|
|
2020
Q2 | $20.3M | Sell |
129,874
-157,000
| -55% | -$23.9M | ﹤0.01% | 1612 |
|
|
2020
Q1 | $41.4M | Buy |
286,874
+6,528
| +2% | +$1.26M | 0.01% | 872 |
|
|
2019
Q4 | $57.3M | Buy |
280,346
+19,143
| +7% | +$3.49M | 0.01% | 922 |
|
|
2019
Q3 | $21M | Buy |
261,203
+26,351
| +11% | +$2.24M | 0.01% | 1653 |
|
|
2019
Q2 | $22.2M | Buy |
234,852
+2,290
| +1% | +$198K | 0.01% | 1613 |
|
|
2019
Q1 | $19.9M | Buy |
232,562
+3,880
| +2% | +$322K | ﹤0.01% | 1693 |
|
|
2018
Q4 | $12.8M | Sell |
228,682
-3,809
| -2% | -$233K | ﹤0.01% | 1901 |
|
|
2018
Q3 | $19M | Buy |
232,491
+48,561
| +26% | +$3.42M | ﹤0.01% | 1828 |
|
|
2018
Q2 | $6.43M | Buy |
183,930
+53,946
| +42% | +$1.64M | ﹤0.01% | 2546 |
|
|
2018
Q1 | $2.67M | Buy |
129,984
+1,735
| +1% | +$44.7K | ﹤0.01% | 2957 |
|
|
2017
Q4 | $3.63M | Sell |
128,249
-3,602
| -3% | -$100K | ﹤0.01% | 2803 |
|
|
2017
Q3 | $4.1M | Buy |
131,851
+33,805
| +34% | +$1.02M | ﹤0.01% | 2750 |
|
|
2017
Q2 | $3.1M | Buy |
98,046
+27,669
| +39% | +$680K | ﹤0.01% | 2899 |
|
|
2017
Q1 | $1.59M | Buy |
70,377
+7,271
| +12% | +$180K | ﹤0.01% | 3189 |
|
|
2016
Q4 | $1.38M | Buy |
63,106
+1,227
| +2% | +$31K | ﹤0.01% | 3257 |
|
|
2016
Q3 | $1.63M | Buy |
61,879
+10,239
| +20% | +$203K | ﹤0.01% | 3151 |
|
|
2016
Q2 | $1.02M | Buy |
+51,640
| New | +$1M | ﹤0.01% | 3342 |
|
Other funds holding RETA
Northern Trust's RETA Position: Q3 2023 in Review
Northern Trust sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 287,968 shares — an estimated $29.4M sold.
Northern Trust first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $57.3M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Northern Trust reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Northern Trust sold 287,968 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $29.4M.
- Northern Trust first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
- Northern Trust's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $57.3M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Northern Trust's 13F filing for Q3 2023, filed 13 Nov 2023.